FDA DRUG cGMP WARNING LETTERS
This article was originally published in The Gold Sheet
...are showing the agency’s growing emphasis on the function of the quality unit as the key barometer of a firm’s compliance status. The focus on internal quality control oversight is built into FDA’s new systems-based inspection approach, which is currently being piloted in the drug area. The systems approach is intended to improve consistency in the field operations and optimize limited inspection resources, and may mean faster enforcement follow-up as well. The warning letter total and types of problems cited in FY 2000 are similar to the previous year. [The drug and therapeutic biologic cGMP warning letters issued in FY 2000 are listed on pp. 9-16. The listings include the recipient’s name, letter date, plant location, and a description of the problem areas cited.]
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.